RIPK1 and acute lymphoblastic leukemia: Thus, in contrast to SM‐sensitive cells (Loder et al, 2012; Schirmer et al, 2016), the synergism between SM and chemotherapy is independent of RIPK1 in SM‐resistant ALL cells.